Aurinia Pharmaceuticals - AUPH Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AUPH shares.
View AUPH analyst ratings or view top-rated stocks.

6 Wall Street research analysts have issued 12-month price objectives for Aurinia Pharmaceuticals' stock. Their AUPH share price forecasts range from $10.00 to $14.00. On average, they predict the company's share price to reach $12.25 in the next twelve months. This suggests a possible upside of 138.8% from the stock's current price.
View analysts price targets for AUPH or view top-rated stocks among Wall Street analysts.

Aurinia Pharmaceuticals' stock was trading at $22.87 at the beginning of 2022. Since then, AUPH stock has decreased by 77.6% and is now trading at $5.13.
View the best growth stocks for 2022 here.

Aurinia Pharmaceuticals saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 8,290,000 shares, a decrease of 27.7% from the October 31st total of 11,460,000 shares. Based on an average trading volume of 2,530,000 shares, the short-interest ratio is presently 3.3 days.
View Aurinia Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our AUPH earnings forecast.

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) announced its quarterly earnings results on Tuesday, November, 2nd. The biotechnology company reported ($0.39) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by $0.06. The biotechnology company had revenue of $14.67 million for the quarter, compared to analysts' expectations of $14.70 million. Aurinia Pharmaceuticals had a negative trailing twelve-month return on equity of 26.03% and a negative net margin of 89.50%. During the same period last year, the firm earned ($0.28) earnings per share.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aurinia Pharmaceuticals investors own include Tetraphase Pharmaceuticals (TTPH), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), Exelixis (EXEL), AbbVie (ABBV), Amarin (AMRN) and Array Technologies (ARRY).

Aurinia Pharmaceuticals trades on the NASDAQ under the ticker symbol "AUPH."

Aurinia Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.43%), Bellevue Group AG (2.00%), State Street Corp (1.72%), Vanguard Group Inc. (0.85%), Renaissance Technologies LLC (0.52%) and Armistice Capital LLC (0.51%). Insiders that own company stock include Jill Leversage, Joseph M Miller, Matthew Maxwell Donley, Michael Robert Martin, Neil Solomons, Peter Greenleaf, Robert Bindert Huizinga and Stephen P Robertson.
View institutional ownership trends.

Shares of AUPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AUPH stock can currently be purchased for approximately $5.13.

Aurinia Pharmaceuticals (NASDAQ:AUPH) has a market capitalization of $729.02 million and generates $45.60 million in revenue each year. The biotechnology company earns $-180,970,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis.

The company employs 300 workers across the globe.

Aurinia Pharmaceuticals' mailing address is 4464 MARKHAM STREET SUITE 1203, VICTORIA A1, V8Z 7X8. The official website for the company is www.auriniapharma.com. The biotechnology company can be reached via phone at 250-708-4272, via email at ir@auriniapharma.com, or via fax at 250-744-2498.